Improving Outcomes in Alzheimer’s
Disease and Dementia: Emerging Treatment Advances and
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2020 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from February 1, 2021 to March 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Alzheimer’s disease is the most common form of dementia, affecting
an estimated 5 million people in the United States. It is a
cognitive disorder that includes behavioral impairment that
interferes with social and occupational functioning. Over time the
disease destroys large areas of the brain, resulting in cellular
loss and dysfunction, a gradual loss of memory, problems with
reasoning or judgment, disorientation, difficulty in learning, loss
of language skills, and decline in the ability to perform routine
tasks. Although not all memory loss indicates Alzheimer’s disease,
one in ten people over 65 years of age, and over half of those over
85 have Alzheimer’s disease. Currently, 26 million people worldwide
have this dementia. By the year 2050, over 15 million Americans may
be affected with the disease. Alzheimer’s disease care costs $172
billion annually in the United States alone. However, advances in
the science underlying Alzheimer’s are emerging at a rapid rate with
a large number of potential agents undergoing clinical trials.
Diagnosing Alzheimer's requires careful medical evaluation,
including medical history, mental status testing, physical and
neurological exam, blood tests and brain imaging. As the use of
biomarkers continues to grow, the potential for catching Alzheimer’s
disease even earlier is crucial to improving outcomes. While there
is no cure for Alzheimer’s disease or a way to stop or slow its
progression, there are pharmacologic and non-pharmacologic options
that may help treat symptoms. Understanding available options can
help individuals living with the disease and their caregivers to
cope with symptoms and improve a patient’s quality of life. There is
one emerging treatment that has shown high-dose, long-duration
exposure can modify the disease process and provide clinical benefit
to patients with Alzheimer’s. The research has now been developed to
a point where scientists can look beyond treating symptoms to think
about addressing underlying disease processes.
Upon completion of this
activity, participants will be able to:
Discuss the clinical advances and
guidelines for diagnosis of dementia, including screening
methods and key assessments
Assess clinical outcome measures and
diagnostic testing strategies in the evaluation of Alzheimer's
disease and related dementias
Evaluate the safety and efficacy
data of pharmacologic treatments to guide management decisions
Explore the role of investigational
human monoclonal antibodies for the treatment of Alzheimer’s
Analyze emerging treatment
strategies in patients with Alzheimer’s disease
Examine the important roles of
caregivers in managing dementia and the interventions for
||R. Scott Turner, MD, PhD
Professor of Neurology and Director
Memory Disorders Program
Georgetown University Medical Center
has received grants/research support from Biogen, Lilly,
Novartis, Roche/Genentech. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue